Vascular Endothelial Growth Factor–Targeted Therapies in Advanced Renal Cell Carcinoma

Gnarra, 1993, Molecular genetic studies of sporadic and familial renal cell carcinoma, Urol Clin North Am, 20, 207, 10.1016/S0094-0143(21)00481-X

Linehan, 1993, Genetic basis of renal cell cancer, Important Adv Oncol, 47

Gnarra, 1995, Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis, Semin Oncol, 22, 3

Shuin, 1994, Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas, Cancer Res, 54, 2852

Clifford, 1998, Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis, Genes Chromosomes Cancer, 22, 200, 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#

Herman, 1994, Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma, Proc Natl Acad Sci U S A, 91, 9700, 10.1073/pnas.91.21.9700

Ferrara, 2004, Vascular endothelial growth factor: basic science and clinical progress, Endocr Rev, 25, 581, 10.1210/er.2003-0027

Leung, 1989, Vascular endothelial growth factor is a secreted angiogenic mitogen, Science, 246, 1306, 10.1126/science.2479986

Kaelin, 2005, The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing, Biochem Biophys Res Commun, 338, 627, 10.1016/j.bbrc.2005.08.165

George, 2003, The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer, N Engl J Med, 349, 419, 10.1056/NEJMp030061

Kaelin, 2007, The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma, Clin Cancer Res, 13, 680s, 10.1158/1078-0432.CCR-06-1865

Carmeliet, 2005, VEGF as a key mediator of angiogenesis in cancer, Oncology, 69, 4, 10.1159/000088478

Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 9, 669, 10.1038/nm0603-669

Kaelin, 2009, Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein, Cancer, 115, 2262, 10.1002/cncr.24232

Ferrara, 2005, Angiogenesis as a therapeutic target, Nature, 438, 967, 10.1038/nature04483

Iliopoulos, 2006, Molecular biology of renal cell cancer and the identification of therapeutic targets, J Clin Oncol, 24, 5593, 10.1200/JCO.2006.08.8948

Presta, 1997, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, 57, 4593

Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491

Bukowski, 2007, Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer, J Clin Oncol, 25, 4536, 10.1200/JCO.2007.11.5154

Escudier, 2010, Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival, J Clin Oncol, 28, 2144, 10.1200/JCO.2009.26.7849

Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7

Rini, 2008, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206, J Clin Oncol, 26, 5422, 10.1200/JCO.2008.16.9847

Rini, 2010, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206, J Clin Oncol, 28, 2137, 10.1200/JCO.2009.26.5561

Margulis, 2008, Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma, J Urol, 180, 94

Jonasch, 2009, Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 4076, 10.1200/JCO.2008.21.3660

Lockhart, 2010, Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors, J Clin Oncol, 28, 207, 10.1200/JCO.2009.22.9237

Faivre, 2006, Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer, J Clin Oncol, 24, 25, 10.1200/JCO.2005.02.2194

Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574

Motzer, 2006, Sunitinib in patients with metastatic renal cell carcinoma, JAMA, 295, 2516, 10.1001/jama.295.21.2516

Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044

Awada, 2005, Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours, Br J Cancer, 92, 1855, 10.1038/sj.bjc.6602584

Clark, 2005, Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors, Clin Cancer Res, 11, 5472, 10.1158/1078-0432.CCR-04-2658

Moore, 2005, Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors, Ann Oncol, 16, 1688, 10.1093/annonc/mdi310

Strumberg, 2005, Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors, J Clin Oncol, 23, 965, 10.1200/JCO.2005.06.124

Ratain, 2006, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 2505, 10.1200/JCO.2005.03.6723

Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655

Escudier, 2009, Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial, J Clin Oncol, 27, 3312, 10.1200/JCO.2008.19.5511

Escudier, 2009, Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 1280, 10.1200/JCO.2008.19.3342

Hurwitz, 2009, Phase I trial of pazopanib in patients with advanced cancer, Clin Cancer Res, 15, 4220, 10.1158/1078-0432.CCR-08-2740

Hutson, 2010, Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma, J Clin Oncol, 28, 475, 10.1200/JCO.2008.21.6994

Hainsworth

Sternberg, 2010, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol, 28, 1061, 10.1200/JCO.2009.23.9764

Rugo, 2005, Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results, J Clin Oncol, 23, 5474, 10.1200/JCO.2005.04.192

Rixe, 2007, Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study, Lancet Oncol, 8, 975, 10.1016/S1470-2045(07)70285-1

Rini, 2009, Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma, J Clin Oncol, 27, 4462, 10.1200/JCO.2008.21.7034

Rini, 2011, Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase 3 AXIS trial, ASCO

Eskens FA. Proceedings of the 99th annual meeting of the AACR. Philadelphia: American Association of Cancer Research; 2008 [abstract: LB-201].

Bhargava, 2008, Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC), J Clin Oncol, 26

Feldman, 2009, Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 1432, 10.1200/JCO.2008.19.0108

Sosman, 2008, Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC), J Clin Oncol, 26

Merchan, 2009, Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients, J Clin Oncol, 27

Hainsworth, 2010, Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma, J Clin Oncol, 28, 2131, 10.1200/JCO.2009.26.3152

Chow, 2007, Sunitinib: from rational design to clinical efficacy, J Clin Oncol, 25, 884, 10.1200/JCO.2006.06.3602

Data on file. AVEO Pharmaceuticals, Inc.

Garcia JA, Hudes GR, Choueiri TK, et al. Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12–0605/NCT00515697). Presented at: 2010 Genitourinary Cancers Symposium. San Francisco (CA), March 5–7, 2010. [abstract: 326].